Association between immune checkpoint inhibitors and the risk and prognosis of uveitis: a meta-analysis.
Immune checkpoint inhibitors cancer immunotherapy is associated with more than double the risk of uveitis
Association between immune checkpoint inhibitors and the risk and prognosis of uveitis: a meta-analysis.
Immune checkpoint inhibitors (immune checkpoint inhibitors) activate antitumor immunity by targeting immune checkpoint molecules such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death receptor 1 (PD-1), and programmed death-ligand 1 (PD-L1).
We searched PubMed, Embase and Web of Science for cohort studies investigating the association between immune checkpoint inhibitors therapy and uveitis risk as well as prognosis.
immunotherapy patients checked for uveitis were over twice as likely to develop it
In total, five studies comprising 277,790 participants were finally included.
However, no statistically significant association was observed between immune checkpoint inhibitors-associated uveitis and overall survival in the pooled analysis of two studies (HR = 0.69, 95% CI: 0.35 - 1.39, P = 0.30);this finding is based on limited evidence and should be interpreted with caution.
Current evidence indicates that immune checkpoint inhibitors therapy was associated with an increased risk of uveitis.
However, existing evidence regarding the impact of immune checkpoint inhibitors-associated uveitis on overall survival is of very low certainty and associated with a high risk of bias, which precludes drawing reliable conclusions.
Large-scale prospective multicenter real-world cohort studies are therefore warranted.